Genentech, Inc.

F. Hoffmann-la Roche Ag

Hoffmann-la Roche Inc.

Piramed Limited

Tracy Bayliss

Bing-Yan Zhu

Daniel P Sutherlin

Alan G Olivero

Adrian Folkes

Richard A Goldsmith

Tim Heffron

Steven T Staben

Georgette M Castanedo

Simon Mathieu

Janet Gunzner

Sally Oxenford

Steven Huy Do

Aleksandr Kolesnikov

Michael Siu

Irina Chuckowree

Nan Chi Wan

Neil Pegg

Paul Goldsmith

Shumei Wang

Vickie H Tsui

Jennafer Dotson

Christian Wiesmann

Kimberly Malesky

Tim Hancox

Stephen Joseph Shuttleworth

Stephen Shuttleworth

Irina Cchuckowree

Janet Gunzer

Bing-Yang Zhu

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and Ris a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Phosphoinositide 3-kinase inhibitor compounds and methods of use

Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use

Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds

Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Growing community of inventors

Basel, Switzerland

Tracy Bayliss